Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins

Journal of Virology

Volumn 86, Issue 1, 2012, Pages 128-142

  Sellhorn, George ^a,e   Kraft, Zane ^a   Caldwell, Zachary ^a   Ellingson, Katharine ^a   Mineart, Christine ^a   Seaman, Michael S ^b   Montefiori, David C ^c   Lagerquist, Eliza ^a   Stamatatos, Leonidas ^a,d  

^a Seattle BioMed   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Allozyne Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 140; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING SITE; CLADISTICS; CONTROLLED STUDY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; VIRUS ISOLATION;

ANIMALS; CELL LINE; DIMERIZATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN ENGINEERING; RABBITS; RECOMBINANT PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84855910494     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06363-11     Document Type: Article

References (88)

1. Baba TW, et al. 2000. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:200-206.
2. Backliwal G, Hildinger M, Hasija V, Wurm FM. 2008. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol. Bioeng 99:721-727.
3. Barnett SW, et al. 2001. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J. Virol. 75:5526 -5540.
4. Beddows S, et al. 2007. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360:329 -340.
5. Beddows S, et al. 2005. Evaluating the immunogenicity of a disulfidestabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79:8812- 8827.
6. Berman PW, et al. 1992. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J. Virol. 66: 4464-4469.
7. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J. 2007. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21: 693-702.
8. Broder CC, et al. 1994. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 91: 11699-11703.
9. Burton DR, et al. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U. S. A. 108:11181-11186.
10. Chakrabarti BK, et al. 2002. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76:5357-5368.
11. Chakraborty K, et al. 2006. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Biochem. J. 399:483- 491.
12. Chen L, et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123-1127.
13. Cheng-Mayer C, Liu R, Landau NR, Stamatatos L. 1997. Macrophage tropism of HIV-1 and utilization of the CC-CKR5 coreceptor. J. Virol. 71:1657-1661.
14. Cheng-Mayer C, Quiroga M, Tung JW, Dina D, Levy JA. 1990. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J. Virol. 64:4390-4398.
15. Ching L, Stamatatos L. 2010. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop. J. Virol. 84:9932-9946.
16. Cho MW, et al. 2001. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques. J. Virol. 75:2224 -2234.
17. Cole KS, Steckbeck JD, Rowles JL, Desrosiers RC, Montelaro RC. 2004. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J. Virol. 78:1525-1539.
18. Correia BE, et al. 2011. Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. J. Mol. Biol. 405:284 -297.
19. Correia BE, et al. 2010. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18:1116 -1126.
20. Derby NR, et al. 2006. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during ho-mologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J. Virol. 80:8745- 8762.
21. Dey B, et al. 2007. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 81: 5579-5593.
22. Doms RW, Earl PL, Chakrabarti S, Moss B. 1990. Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain. J. Virol. 64: 3537-3540.
23. Doria-Rose NA, et al. 2005. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 79:11214 -11224.
24. Du SX, et al. 2011. A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein. PLoS One 6:e20927.
25. Earl P, Moss LB, Doms RW. 1991. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J. Virol. 65:2047-2055.
26. Earl PL, et al. 1994. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68:3015-3026.
27. Earl PL, Doms RW, Moss B. 1990. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 87:648-652.
28. Earl PL, Koenig S, Moss B. 1991. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 65:31- 41.
29. Earl PL, Moss B. 1993. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein. AIDS Res. Hum. Retroviruses 9:589 -594.
30. Flynn NM, et al. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191: 654-665.
31. Gao F, et al. 2005. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 groupmconsensus envelope glycoprotein. J. Virol. 79:1154 -1163.
32. Garrity RR, et al. 1997. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 159: 279-289.
33. Gorse GJ, et al. 1999. HIV-1MN recombinant glycoprotein 160 vaccineinduced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 15:115-132.
34. Grundner C, et al. 2005. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. Virology 331:33- 46.
35. Gzyl J, et al. 2004. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses. Virology 318:493-506.
36. Haigwood NL, et al. 1992. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 66:172-182.
37. Hessell AJ, et al. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15: 951-954.
38. Hessell AJ, et al. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433.
39. Ho J, MacDonald KS, Barber BH. 2002. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. Vaccine 20:1169 -1180.
40. Hoxie JA. 2010. Toward an antibody-based HIV-1 vaccine. Annu. Rev. Med. 61:135-152.
41. Hu SL, Stamatatos L. 2007. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5:507-513.
42. Jeffs SA, Shotton C, Balfe P, McKeating JA. 2002. Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J. Gen. Virol. 83: 2723-2732.
43. Keefer MC, et al. 1996. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 12:683- 693.
44. Kim YB, Han DP, Cao C, Cho MW. 2003. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 305:124 -137.
45. Kothe DL, et al. 2007. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360:218 -234.
46. Kothe DL, et al. 2006. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352:438-449.
47. Kraft Z, et al. 2008. Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses. J. Virol. 82:5912-5921.
48. Law M, Cardoso RM, Wilson IA, Burton DR. 2007. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 81:4272- 4285.
49. Li M, et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80:11776 -11790.
50. Li Y, et al. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 82:638-651.
51. Liang X, et al. 1999. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 17:2862-2872.
52. Liao HX, et al. 2006. A groupMconsensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353:268 -282.
53. Lorin C, et al. 2004. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J. Virol. 78:146 -157.
54. Lu S, et al. 1998. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/V2 and V3 regions. AIDS Res. Hum. Retroviruses 14:151-155.
55. Mascola JR, et al. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73:4009-4018.
56. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413- 444.
57. Mascola JR, et al. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J. Infect. Dis. 173:340 -348.
58. Mascola JR, et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
59. Nara PL, et al. 1988. Purified envelope glycoproteins from human immunodeficiency virus type I variants induce individual, type-specific neutralizing antibodies. J. Virol. 62:2622-2628.
60. Nishimura Y, et al. 2003. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. U. S. A. 100: 15131-15136.
61. Nkolola JP, et al. 2010. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J. Virol. 84:3270 -3279.
62. Ofek G, et al. 2010. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. U. S. A. 107:17880 -17887.
63. Ou W, Lu N, Yu SS, Silver J. 2006. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5. J. Virol. 80:2539 -2547.
64. Pantophlet R, Wilson IA, Burton DR. 2003. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77:5889 -5901.
65. Parren PW, et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75: 8340-8347.
66. Quinones-Kochs MI, Buonocore L, Rose JK. 2002. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J. Virol. 76:4199-4211.
67. Richardson JTM, et al. 1996. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J. Virol. 70:753-762.
68. Salzwedel K, Berger EA. 2000. Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41. Proc. Natl. Acad. Sci. U. S. A. 97:12794 -12799.
69. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
70. Saunders CJ, et al. 2005. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J. Virol. 79:9069 -9080.
71. Seaman MS, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452.
72. Seaman MS, et al. 2007. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology 367:175-186.
73. Sellhorn G, Caldwell Z, Mineart C, Stamatatos L. 2009. Improving the expression of recombinant soluble HIV envelope glycoproteins using pseudo-stable transient transfection. Vaccine 28:430-436.
74. Shibata R, et al. 1999. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5:204 -210.
75. Shioda T, Levy JA, Cheng-Mayer C. 1991. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349:167-169.
76. Srivastava IK, et al. 2003. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol. 77:11244-11259.
77. Srivastava IK, et al. 2002. Purification and characterization of oligomeric envelope glycoprotein from a primary r5 subtype B human immunodeficiency virus. J. Virol. 76:2835-2847.
78. Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L. 2003. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J. Virol. 77:2310-2320.
79. Stamatatos L, Lim M, Cheng-Mayer C. 2000. Generation and structural analysis of soluble oligomeric envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 16:981-994.
80. Stamatatos L, Wiskerchen M, Cheng-Mayer C. 1998. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV-1 isolate on viral envelope structure, cell-entry and replication. AIDS Res. Hum. Retroviruses 14:1129 -1139.
81. VanCott TC, et al. 1997. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71:4319-4330.
82. VanCott TC, et al. 1999. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J. Virol. 73:4640-4650.
83. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
84. Wang S, et al. 2006. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350:34-47.
85. Weiss CD, Levy JA, White JM. 1990. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J. Virol. 64:5674 -5677.
86. Yang X, Wyatt R, Sodroski J. 2001. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J. Virol. 75:1165-1171.
87. Yang ZY, et al. 2004. Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J. Virol. 78:4029-4036.
88. Zhang PF, Jr, et al. 2007. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl. Acad. Sci. U. S. A. 104:10193-10198.